MX2023004942A - Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents

Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.

Info

Publication number
MX2023004942A
MX2023004942A MX2023004942A MX2023004942A MX2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
bicyclic compounds
compounds
compositions
Prior art date
Application number
MX2023004942A
Other languages
English (en)
Spanish (es)
Inventor
Robert Taylor
Douglas Boatman
Leen Kawas
Kevin Church
Jewel Johnston
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of MX2023004942A publication Critical patent/MX2023004942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023004942A 2020-11-02 2021-11-01 Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. MX2023004942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MX2023004942A true MX2023004942A (es) 2023-07-06

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004942A MX2023004942A (es) 2020-11-02 2021-11-01 Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (1) US20240025903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236944A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884275B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230104191A (cg-RX-API-DMAC7.html)
CN (2) CN116568301A (cg-RX-API-DMAC7.html)
AR (1) AR124637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021371026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196582A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001195A1 (cg-RX-API-DMAC7.html)
IL (1) IL302465A (cg-RX-API-DMAC7.html)
MX (1) MX2023004942A (cg-RX-API-DMAC7.html)
TW (1) TWI918751B (cg-RX-API-DMAC7.html)
WO (1) WO2022094400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
KR20250005323A (ko) * 2022-05-04 2025-01-09 아티라 파마, 인코포레이티드 신경병증을 치료하는 방법
US20250275976A1 (en) * 2022-05-04 2025-09-04 Athira Pharma, Inc. Methods of Treating Neuroinflammatory Conditions
JP2025538382A (ja) 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
US8691819B2 (en) * 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
EP3366687B1 (en) * 2015-09-18 2020-04-29 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis

Also Published As

Publication number Publication date
EP4236944A1 (en) 2023-09-06
TWI918751B (zh) 2026-03-21
CL2024000340A1 (es) 2024-08-16
CN116568301A (zh) 2023-08-08
US20240025903A1 (en) 2024-01-25
CN119684295A (zh) 2025-03-25
CA3196582A1 (en) 2022-05-05
AU2021371026A1 (en) 2023-06-15
JP2023550543A (ja) 2023-12-01
AU2021371026A9 (en) 2024-04-18
JP7884275B2 (ja) 2026-07-03
KR20230104191A (ko) 2023-07-07
AR124637A1 (es) 2023-04-19
IL302465A (en) 2023-06-01
CL2023001195A1 (es) 2023-10-20
TW202233622A (zh) 2022-09-01
EP4236944A4 (en) 2024-09-04
WO2022094400A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EP4620469A3 (en) Tricyclic urea compounds as jak2 v617f inhibitors
EP4438114A3 (en) Methods of making bempedoic acid and compositions of the same
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MY207223A (en) Prodrug modulators of the integrated stress pathway
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021011488A (es) Compuestos y usos de estos.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
MX2025002953A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis
MX2022006807A (es) Análogos de rapamicina y usos de estos.
PH12022500021A1 (en) Il-17a modulators
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MY140169A (en) Compounds, compositions, and methods
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2022000712A (es) Moduladores de nlrp3.
MX2024011254A (es) Moduladores de nlrp3
CR20230408A (es) Compuestos moduladores de gcn2 y usos de los mismos
MX2025007184A (es) Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos
MX2022011576A (es) Moduladores de nlrp3.
WO2020154571A8 (en) Compounds and uses thereof
CR20240447A (es) Compuestos de urea tricíclica como inhibidores de v617f de jak2.
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
MX2024007220A (es) Psicoplastogenos de pirrolidina fusionada y sus usos.